|

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

RECRUITINGPhase 2/3Sponsored by Ain Shams University
Actively Recruiting
PhasePhase 2/3
SponsorAin Shams University
Started2024-07-10
Est. completion2025-06-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06441591

Summary

The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years,
* Type II diabetic patients with CKD stage 3 (eGFR = 30 - 59 ml/min) or stage 4 (eGFR 15-29 ml/min),
* Albumin/Creatinine ratio (ACR): 30 - 300 μg /mg (microalbuminuria),
* Stable standard therapy for at least three months prior to inclusion in the study.

Exclusion Criteria:

* Kidney donor or recipient,
* Active malignancy,
* Pregnancy or breastfeeding,
* Known intolerance or hypersensitivity to VPN,
* Participation in other interventional trials,
* Patients with inadequate liver function (ALT and AST three times greater than the upper normal limits),
* Patients with severe comorbidities
* Patients receiving warfarin

Conditions3

DiabetesDiabetic Kidney DiseaseDiabetic Nephropathies

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.